龙津药业即将摘牌退市 “散户”杨芳在最后一个交易日前增持243万股

Core Viewpoint - The article discusses the unusual behavior of a shareholder, Yang Fang, who increased his stake in Longjin Pharmaceutical just before its delisting, raising questions about the motivations behind such actions in the context of a company facing imminent delisting [1][2]. Group 1: Shareholder Activity - Yang Fang increased his holdings in Longjin Pharmaceutical from 4.71% to 5.32% by purchasing 2.436 million shares at an average price of 0.66 yuan per share, amounting to approximately 14.06 million yuan [2]. - Prior to this purchase, Yang had sold all his shares in March 2024 at an average price of 1.67 yuan per share, indicating a significant change in his investment strategy [1][2]. Group 2: Market Context - The last trading day for Longjin Pharmaceutical was June 26, 2024, following a 20-day delisting preparation period, highlighting the urgency and risk associated with investing in a company on the brink of delisting [1]. - The behavior of increasing stakes before delisting is rare in the A-share market, as most investors tend to avoid such investments due to the high risks involved, including limited trading options and potential for further price declines post-delisting [3].